480 related articles for article (PubMed ID: 31449981)
1. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
4. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
[TBL] [Abstract][Full Text] [Related]
5. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
6. [
Metser U; Kulanthaivelu R; Salawu A; Razak A; Mak V; Li X; Langer DL; MacCrostie P; Singnurkar A
J Nucl Med; 2023 Sep; 64(9):1371-1377. PubMed ID: 37414444
[TBL] [Abstract][Full Text] [Related]
7. Utilization of positron emission tomography in the management of patients with sarcoma.
Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis.
Kubo T; Furuta T; Johan MP; Ochi M
Eur J Cancer; 2016 May; 58():104-11. PubMed ID: 26990930
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging of sarcomas with FDG PET.
Mendoza H; Nosov A; Pandit-Taskar N
Skeletal Radiol; 2023 Mar; 52(3):461-475. PubMed ID: 36173459
[TBL] [Abstract][Full Text] [Related]
10. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of
Kassem TW; Abdelaziz O; Emad-Eldin S
Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence.
Fendler WP; Chalkidis RP; Ilhan H; Knösel T; Herrmann K; Issels RD; Bartenstein P; Cyran CC; Lindner LH; Hacker M
Eur Radiol; 2015 Aug; 25(8):2214-21. PubMed ID: 25693667
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of
Liu F; Zhang Q; Zhou D; Dong J
BMC Cancer; 2019 Apr; 19(1):323. PubMed ID: 30953476
[TBL] [Abstract][Full Text] [Related]
14. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.
Liu F; Zhang Q; Zhu D; Liu F; Li Z; Li J; Wang B; Zhou D; Dong J
Medicine (Baltimore); 2015 Sep; 94(36):e1462. PubMed ID: 26356700
[TBL] [Abstract][Full Text] [Related]
15. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
17. Functional image in soft tissue sarcomas: An update of the indications of
Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
[TBL] [Abstract][Full Text] [Related]
18. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
19. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
[TBL] [Abstract][Full Text] [Related]
20. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.
Younis MH; Abu-Hijleh HA; Aldahamsheh OO; Abualruz A; Thalib L
Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
